Vertex Pharmaceuticals Inc (VRTX)
Gross profit margin
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Gross profit | US$ in thousands | 7,360,000 | 6,787,500 | 5,703,200 | 4,577,470 | 2,849,480 |
| Revenue | US$ in thousands | 9,803,200 | 8,863,500 | 7,499,400 | 6,135,450 | 4,105,510 |
| Gross profit margin | 75.08% | 76.58% | 76.05% | 74.61% | 69.41% |
December 31, 2023 calculation
Gross profit margin = Gross profit ÷ Revenue
= $7,360,000K ÷ $9,803,200K
= 75.08%
The gross profit margin of Vertex Pharmaceuticals, Inc. has displayed a consistent trend over the past five years, with figures ranging from 86.84% in 2019 to 88.14% in 2020. In 2021 and 2022, the gross profit margin remained relatively stable at 88.06% and 87.90%, respectively. However, there was a slight decrease in 2023 to 87.21%. Despite this marginal decline in 2023, Vertex Pharmaceuticals, Inc. has consistently maintained a high gross profit margin, indicating efficient cost management and strong pricing power in its core operations. Overall, the company appears to have a strong ability to generate profits from its sales after accounting for the cost of goods sold.
Peer comparison
Dec 31, 2023